Azafaros

Series-B+
azafaros.com Biotech & Healthcare Leiden, The Netherlands 11-50
Total Funding $177M
Latest Round $150M Series-B+
Last Announced May 13, 2025
Investors 7 Backers
Decision Makers 5 Verified

About Azafaros

Azafaros develops therapeutic agents for rare metabolic disorders, specifically lysosomal storage disorders. It focuses on an orally available azasugar, nizubaglustat, designed to treat the central nervous system and interfere with glycosphingolipid metabolism. Azafaros licenses these agents.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B+
Global Headquarters Leiden, The Netherlands
Team Size 11-50
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website azafaros.com
Domain Registered Date Apr 17, 2018

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

3 Events
  1. Capital Raise

    Raised $150,000,000 · Series-B+

    startupintros.com

  2. Capital Raise

    Raised $27,000,000 · Series-A

    startupintros.com

  3. Milestone

    Website domain registered

    azafaros.com

Investors & Backers

7
BioGeneration Ventures
BioMedPartners
Forbion Capital Partners
Jeito Capital
Pictet Alternative Advisors
Schroders Capital
Seroba Life Sciences

Funding History

2 Rounds
Series-B+ · May 13, 2025
$150,000,000 startupintros.com
Series-A · Feb 1, 2020

Founders & Leadership

3

Amy Sullivan

Chief Financial Officer

Work email & phone locked Unlock →

Olivier Morand

Founder

Work email & phone locked Unlock →

Stefano Portolano

Chief Executive Officer

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts